The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Prognostic value of early bone marrow MRD status in CAR-T therapy for multiple myeloma
Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, gives a summary of the results of a study evaluating the prognostic value of early bone marrow (BM) measurable residual disease (MRD) status in patients with multiple myeloma treated with CAR-T therapy. The study found that early BM MRD negativity was a prognostic factor for survival and response regardless of cellularity and free light chain normalization at month one. In addition, patients who are MRD-positive at month one were found to have a low likelihood of achieving MRD negativity. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
